Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Amicus Therapeutics (FOLD) Accumulated Depreciation & Amortization (2016 - 2025)

Amicus Therapeutics' Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $7.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 12.72% year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Dec 2025, down 12.72%, and an annual FY2025 reading of $7.5 million, down 12.72% over the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $7.5 million at Amicus Therapeutics, up from $5.6 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $8.5 million in Q4 2024, with the low at $1.3 million in Q1 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $4.2 million, with a median of $4.2 million recorded in 2022.
  • Year-over-year, Accumulated Depreciation & Amortization tumbled 58.8% in 2021 and then soared 159.6% in 2023.
  • Tracing FOLD's Accumulated Depreciation & Amortization over 5 years: stood at $6.2 million in 2021, then dropped by 13.96% to $5.3 million in 2022, then skyrocketed by 47.38% to $7.9 million in 2023, then grew by 8.56% to $8.5 million in 2024, then fell by 12.72% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Accumulated Depreciation & Amortization are $7.5 million (Q4 2025), $5.6 million (Q3 2025), and $3.7 million (Q2 2025).